Stelara

Autoimmune drug pipeline: What health execs should watchNew drugs for RA, psoriasis, type 1 diabetes and Crohn’s disease—some recently approved and others coming down the pipeline—could have an impact on the industry.
Clear skin within reach for psoriasis patientsNew data presented at the 25th European Academy of Dermatology and Venereology (EADV) Congress in Vienna, Austria, this week shows that secukinumab (Cosentyx, Novartis) has long-lasting skin clearance in patients with moderate-to-severe plaque psoriasis.
AAD 2015: Secukinumab improves skin clearance in plaque psoriasis patients over widely used therapyPlaque psoriasis patients treated with secukinumab (Cosentyx) over ustekinumab (Stelara)—a widely used biologic—can achieve clearer skin, according to a late-breaking research session at the 73rd Annual Meeting of the American Academy of Dermatology (AAD), in San Francisco.
Drugs in Perspective: Otezla (apremilast)Otezla (apremilast), a small-molecule inhibitor of phosphodiesterase 4 (PDE4), was approved by FDA on March 21, 2014, for the treatment of adult patients with active psoriatic arthritis. On September 23, 2014, it was approved for a second indication, the treatment of patients with moderate-to-severe plaque psoriasis who are candidates for phototherapy or systemic therapy
Ustekinumab approval expands options for psoriatic arthritisThe human interleukin 12 and interleukin 23 inhibitor ustekinumab is now approved for the treatment of active psoriatic arthritis.
FDA approves Stelara for psoriatic arthritisThe Food and Drug Administration has approved Stelara (ustekinumab, Janssen Biotech) alone or in combination with methotrexate for the treatment of psoriatic arthritis in patients ages 18 and older.
FDA approves first anti-IL-12/23 psoriatic arthritis drugFDA has approved ustekinumab (Stelara, Janssen Biotech) alone or in combination with methotrexate for active psoriatic arthritis in adult patients aged 18 years and older.
Sustainability of ustekinumab established in patients with psoriatic arthritis
Sustainability of ustekinumab established in patients with psoriatic arthritisThe human interleukin-12 and interleukin-23 (IL-12/IL-23) inhibitor ustekinumab (Stelara, Janssen) is effective and is well tolerated in patients who have active psoriatic arthritis.